Vitreous Tamponades Market: Focus to Develop Newer Products to Capture Larger Market Share

Health

A highly fragmented global vitreous tamponades market is distinctive in terms of dominance of a select number of players in each region. Keen players in the market have given thrust to research and development to introduce newer products to serve the demand for case-specific products for specialty medical procedures.

The global market for vitreous tamponades is primarily driven by the increasing incidence of retinal detachment, diabetic retinopathy, macular pucker, and other retinal disorders. As per statistics of the International Diabetes Federation, around 300 million diabetes cases were reported in 2010 globally and it is estimated to reach 438 million by 2030. The rising incidence of diabetes that is related to be a major cause of diabetic retinopathy and other retinal disorders is stoking the demand for tamponades to prevent impaired vision and even blindness.

Besides this, the growing geriatric population that is more susceptible to retinal breaks is also a key factor boosting the growth of vitreous tamponades market.

Request for the Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4233

A report by Transparency Market Research (TMR) estimates the global vitreous tamponades market to attract a revenue of US$89.9 mn by the end of 2025 from US$69.3 mn in 2016 at a CAGR of 3.0% for the forecast period between 2017 and 2025.

The report studies the global vitreous tamponades market on the basis of product type, end-user, and geography. Based on product type, the global vitreous tamponades market is divided into gaseous tamponades and liquid tamponades. Vis-à-vis revenue, of the two, liquid tamponades segment led the global vitreous tamponades market in 2016 accounting for 53.9% market share. The supremacy of the segment is due to the extensive use of liquid tamponades in European and Asian region for the treatment of retinal detachments, giant tears, proliferative diabetic retinopathy, and proliferative vitreoretinopathy. The segment of liquid tamponades has been further sub-segmented into silicone oil and perflurocarbon liquid. Of the two, silicone oil is anticipated to surpass in terms of growth rate during the 2017-2025 forecast period. On the other hand, the perflurocarbons liquid segment is likely to witness constant growth over the 2017-2025 forecast period as they are primarily used for the reattachment of giant retinal tears.

Gaseous tamponades, on the other hand, is expected to display the leading growth rate in the upcoming years. This is mainly because of low risk of emulsification, low cost, and ease of use. SF6, C2F8, and perfluropropane are the most common types of gaseous tamponades used in vitreoretinal surgeries worldwide. These gases offer advantages of being expansive that allows the retina and eyeball to gradually adjust to the occupying volume of the eye for better healing.

Based on end-user, the global vitreous tamponades market has been segmented into hospitals and ophthalmology clinics. Of the two, ophthalmology clinics held the leading share of the market in terms of revenue in 2016.

In terms of geography, the global vitreous tamponades market has been segmented into four major regions: North America, Asia Pacific, Europe, and Rest of the World. Powered by the U.S., North America held supremacy in terms of revenue over other key regions in the overall market in 2016. In the U.S., retinal detachment accounts as a major cause for morbidity with an incidence of 10.1 to 17.9 per 100,000 individuals.

Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4233

Asia Pacific, on the other hand, is anticipated to emerge as a promising region and display increased market share over the forecast period from 2017 to 2025.

Leading players in the global vitreous tamponades market include Novartis AG, Valeant Pharmaceuticals, Dutch Ophthalmic Research Center B.V., AL. CHI. MI.A srl, Fluron GmbH, and Carl Zeiss Meditech AG.